Clintrial s.r.o.

Prague 10 69 trials 27 recruiting

69 Registered trials

27 Currently recruiting

Organisation

Clintrial s.r.o.

Location

Prague 10, Czechia

Identifier

ORG-100042931

Address

Pocernicka 1427/16, Strasnice, 100 00, Czechia

Departments

42005: Dermatologie / Dermatology
Clintrial
CLINTRIAL s.r.o.
CLINTRIAL, s.r.o.
Dermatology
N/A
NA
Neurologické oddělení
Neurologie
Neurology
Psychiatrická ambulance
Psychiatry
Revmatologie

Clinical trials at this site (69)

Search interface

A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended

2024-511057-22-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-12-04
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine Ended

2023-507942-10-00 Major depressive disorder 4 2024-07-31
An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive … Ended

2023-506570-12-01 Cognitive disorder 4 2024-06-13
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended

2023-503522-40-01 Atopic Dermatitis 4 2024-04-10
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis Ended

2022-502997-18-00 Atopic Dermatitis 3 2024-02-02
A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended

2022-500777-14-00 Atopic Dermatitis 4 2023-11-06
A study to understand how well DC806 works and how safe it is in participants with plaque psoriasis Ended

2022-502249-90-00 Plaque Psoriasis 4 2023-08-31
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended

2023-508163-74-00 Major Depressive Disorder 5 2023-06-12
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25
Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment o… Ended

2022-500538-27-00 Adjunctive therapy to antidepressants for the treatmen 10 2023-03-30
A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in… Ended

2023-510047-37-00 Treatment-resistant depression (TRD) 4 2023-03-30
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended

2023-507096-21-00 Chronic or Episodic Migraine (Migraine without aura, mi 5 2021-08-16
A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended

2024-512123-37-00 Parkinson's disease 5 2021-05-27
Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended

2023-509801-59-00 Alopecia areata 5 2020-07-09
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12
Phase 3b/4 Study in Rheumatoid Arthritis Ended

2023-508022-10-00 Rheumatoid Arthritis 6 2019-07-25
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended

2022-502233-25-00 Schizophrenia 5